tiprankstipranks
Ionis Pharmaceuticals (IONS)
NASDAQ:IONS

Ionis Pharmaceuticals (IONS) Ownership - Who Owns Ionis Pharmaceuticals?

1,217 Followers

Ionis Pharmaceuticals (IONS) Ownership Overview

2.95%36.47%50.82%9.76%
50.82% Other Institutional Investors
9.76% Public Companies and
Individual Investors
The ownership structure of Ionis Pharmaceuticals (IONS) stock is a mix of institutional, retail and individual investors. Approximately 87.29% of the company’s stock is owned by Institutional Investors, 2.95% is owned by Insiders and 9.76% is owned by Public Companies and Individual Investors.
The ownership structure of Ionis Pharmaceuticals (IONS) stock is a mix of institutional, retail and individual investors. Approximately 87.29% of the company’s stock is owned by Institutional Investors, 2.95% is owned by Insiders and 9.76% is owned by Public Companies and Individual Investors.

Recent Insider Trading Activity

Date
Name
Activity
Value
Feb 16, 2024
Brett Monia
Ceo,director
Sold$17218
Feb 02, 2024
Eric Swayze
Evp Research
Sold$560196
Jan 29, 2024
Brett Monia
Ceo,director
Sold$118249
Jan 29, 2024
Patrick O'neil
Evp Clo & Gc
Sold$333788

Recent Hedge Fund Trading Activity

Date
Firm
Activity
Value
Dec 31, 2023Sold$353573
Dec 31, 2023Sold$633639
Dec 31, 2023Bought$78668461
Dec 31, 2023Sold$96376783

Top Shareholders

Holder
# of Shares
Type
% Holding
Value
12,463,660.00Institution8.55%548,151,766.80
11,717,269.00Institution8.04%515,325,490.62
11,467,444.00Institution7.87%504,338,187.12
4,725,400.00Institution3.24%207,823,092.00
4,025,493.00Institution2.76%177,041,182.14
3,454,676.00Institution2.37%151,936,650.48
2,954,743.00Institution2.03%129,949,597.14
2,212,149.00Institution1.52%97,290,313.02
1,905,056.00Institution1.31%83,784,362.88
1,757,237.00Institution1.21%77,283,283.26

Top Mutual Fund Holders

Holder
# of Shares
Type
% Holding
Value
11,717,269.00Institution8.04%515,325,490.62
11,467,444.00Institution7.87%504,338,187.12
4,725,400.00Institution3.24%207,823,092.00
2,954,743.00Institution2.03%129,949,597.14
2,212,149.00Institution1.52%97,290,313.02
1,757,237.00Institution1.21%77,283,283.26
1,646,123.00Institution1.13%72,396,489.54
1,395,608.00Institution0.96%61,378,839.84
1,194,071.00Institution0.82%52,515,242.58
1,120,349.00Institution0.77%49,272,949.02

Top ETF Holders

Holder
# of Shares
Type
% Holding
Value
4,283,107.00Institution2.94%220,108,869.00
3,480,667.00Institution2.39%178,871,477.00
2,114,523.00Institution1.45%108,665,337.00
1,941,569.00Institution1.33%99,777,231.00
1,661,320.00Institution1.14%72,317,259.60
1,479,450.00Institution1.02%65,066,211.00
1,062,187.00Institution0.73%46,714,984.26
674,995.00Institution0.46%29,382,532.35
558,554.00Institution0.38%24,565,204.92
436,680.00Institution0.30%22,440,985.00

FAQ

Who Owns Ionis Pharmaceuticals (IONS)?
According to the latest TipRanks data, approximately 50.82% of the company's stock is held by institutional investors, 2.95% is held by insiders, and 9.76% is held by retail investors.
    What percentage of Ionis Pharmaceuticals (IONS) stock is held by institutional investors?
    According to the latest TipRanks data, approximately 50.82% of Ionis Pharmaceuticals (IONS) stock is held by institutional investors.
      What percentage of Ionis Pharmaceuticals (IONS) stock is held by retail investors?
      According to the latest TipRanks data, approximately 9.76% of Ionis Pharmaceuticals (IONS) stock is held by retail investors.
        Who owns the most shares of Ionis Pharmaceuticals (IONS)?
        Vanguard owns the most shares of Ionis Pharmaceuticals (IONS).
          What is the significance of the ownership structure for a publicly traded company?
          The ownership structure can impact the company's decision making, as large institutional investors may exert influence on the company's management and can also affect the company's stock price with their buying and selling patterns.
            What's Included in PREMIUM?
            Make informed decisions based on Top Analysts' activity
            Know what industry insiders are buying
            Get actionable alerts from top Wall Street Analysts
            Find out before anyone else which stock is going to shoot up
            Get powerful stock screeners & detailed portfolio analysis